Janux Therapeutics Inc is a trailblazer in the biopharmaceutical field, focusing on creating innovative immunotherapies for cancer treatment. Leveraging its proprietary technologies, TRACTr and TRACIr, the company is developing treatments that activate the body's own T cells to fight tumors. With a pipeline targeting various cancer markers such as PSMA, EGFR, and TROP2, Janux is dedicated to advancing cancer care. Founded in 2017 and based in San Diego, California, Janux is at the forefront of developing therapies that aim to transform cancer treatment.
Wall Street analysts reshuffled the deck on Monday with a wave of upgrades, downgrades, and fresh initiations spanning pharma giants, fast-casual chains, and streaming players. Find out which names got bullish bets…
Pre-Market Stock Futures: The futures are trading flat after a stellar day across Wall Street, with all major indices finishing deep in positive territory. Traders cited an improving outlook for the Iran…
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry significant risk, but their…
